Thought Leadership

Latest Report

Pharma’s Biggest Spenders 2022 Infographic

As several of the big 11 pharma companies dialled back on acquisitions, the collective bill for M&A and R&D activities among this cohort took a dip for the second consecutive year in 2022, even as Pfizer marched on with its spending spree. Their collective expenditure – $157 billion – might be the smallest since 2018, but it's still a…

Report library

Thumbnail

Evaluate Vantage 2020 Preview

The Evaluate Vantage 2020 Preview predicts a rocky year ahead, with areas of significant growth contrasting with investor uncertainty. The industry closed 2019 with a…

Thumbnail

EvaluatePharma Orphan Drug Report 2019

$242bn forecasted orphan drug sales by 2024, one-fifth of the total worldwide pharmaceutical market The EvaluatePharma Orphan Drug Report 2019 arrives at the start of a…

Thumbnail

Vantage 2019 Preview

2019 expected to be volatile year for pharma and biotech industries The Vantage 2019 Preview looks at the risks and opportunities for the year ahead. Report…